ASSOCIATIONS OF INTERLEUKIN-6 AND INTERLEUKIN-10 WITH SOME INDICATORS OF THE SEVERITY OF CHRONIC HEART FAILURE AGAINST THE BACKGROUND OF RHEUMATOID ARTHRITIS
https://doi.org/10.52485/19986173_2021_2_10
Abstract
The aim. Comparative analysis of the levels of interleukin-6 (IL-6) and interleukin-10 (IL-10) in patients with chronic heart failure (CHF) and rheumatoid arthritis, as well as the search for possible associations with the morphofunctional parameters of the myocardium.
Materials and methods. The study group consisted of 134 patients with CHF with RA, and the comparison group consisted of 122 patients with CHF without RA. Functional class of CHF, who participated in the study of patients according to NYHA I-II. The volume of CHF therapy in the study group and the comparison group were compared. The basic anti - inflammatory drug for the treatment of RA is methotrexate. The morphofunctional parameters of the myocardium were evaluated, as well as the levels of IL-6 and IL-10 and their possible relationship with the morphofunctional parameters of the myocardium. The processing was carried out using the program STATISTICA 10.0; the paper presents statistically reliable results. The critical level of significance when testing statistical hypotheses is p <0.05.
Results. Statistically significant differences in the values of IL-6 were revealed: in the group of CHF and RA, the level was 18.3±5.05 pg / ml; in the group of CHF without RA, 5.3±1.9 pg / ml (p=0.004). Comparative analysis of IL-10 levels revealed no significant differences: 5.9±1.9 pg / ml and 5.2±0.7 pg / ml, respectively (p=0.4). In the group of CHF and RA, statistically significant correlations of IL-10 with LVEF (r=-0.1; p=0.02) and NT-proBNP (r=-0.1; p=0.04), as well as IL-6 with NT-proBNP (r=0.06; p=0.03) were obtained.
Conclusion. Taking into account the obtained associations, it can be assumed that the increase in the concentration of IL-6 may lead to the destabilization of the course of CHF against the background of RA, but to confirm this theory, prospective studies are necessary.
About the Authors
A. S. Ankudinov
Irkutsk state medical University
Russian Federation
Russian Federation
1 Krasnogo Vosstaniya str., Irkutsk, 664003
A. N. Kalyagin
Irkutsk state medical University
Russian Federation
Russian Federation
1 Krasnogo Vosstaniya str., Irkutsk, 664003
E. E. Vikhareva
Irkutsk City Clinical Hospital 1
Russian Federation
Russian Federation
664049, Irkutsk, Yubileiny, 100
References
1. Lam C.S., Donal E., Kraigher-Krainer E., Vasan R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011. 8(1).18-28. DOI: 10.1093/eurjhf/hfq121.
2. Polyakov D.S., Fomin I.V., Alikulova F.Y., Weisberg R.A., Kraiem N., Badin Y.V., etc. the Epidemiological program AGE–CHF: decompensation of chronic heart failure in clinical practice (AGE–D–CHF). Journal Of Heart Failure. 2016. 17 (6). 299-305. DOI: 10.18087/rhfj.2016.5.2239. in Russian.
3. Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we should do. Russian cardiology journal. 2016. 8. 7-13. DOI:10.15829/1560-4071-2016-8-7-13/ in Russian.
4. Belenkov Yu. N, Fomin I. V, Mareev V.Y., Ageev F.T., Badin, Yu., A.S. Galyavich, etc. the Prevalence of chronic heart failure in the European part of the Russian Federation data AGE– CHF (part 2). Journal of Heart Failure. 2006. 7 (3). 3-7. in Russian.
5. Lang C.C., Mancini D.M. Non-cardiac comorbidities in chronic heart failure. Heart. 2007. 93 (6)/ 665-71.
6. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage. 2014. 22(3). 363-388. DOI: 10.1016/j.joca.2014.01.003
7. Udachkina E.V., Novikova D.S., Popkova T.V., Nasonov E.L. Rheumatoid arthritis and atherosclerosis: the role of interleukin-6. Clinical pharmacology and therapy. 2012. 21(1). 86- 92. in Russian.
8. Glezeva N., Baugh J.A. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews. 2014. 19 (5). 681–694. DOI: 10.1007/s10741-013-9405-8.
9. Mareev V.U., Fomin I.V., Ageev F. T., etc. Clinical recommendations of the OSS-RKORNMOT. Heart failure: chronic and acute decompensated. Diagnosis, prevention and treatment. Cardiology. 2018. 58. 6s. 8-158. DOI: 10.18087/cardio. 2475. in Russian.
10. Clinical recommendations: chronic heart failure. Russian Cardiological Society [Electronic resource]. National society for the study of heart failure and myocardial diseases-2020. http://cr.rosminzdrav.ru/schema/156. (last accessed: 17.01.2021). in Russian.
11. Nasonov E. L. Treatment of rheumatoid arthritis-2017. Clinical pharmacology antherapy. 2017. 26 (1). 4-10. in Russian.
12. Rebrova, O.Yu. Statistical analysis of medical data. Application of the STATISTICA application software package. Moscow: MediaSfera, 2002. 312 p. in Russian.
13. Gulatava N., Tabagari N., Talakvadze T. et al. Demographic and clinical factors associated with increased il-6 levels in ambulatory patients with chronic heart failure. Georgian Med News. 2020 Nov; (308): 52-58.
14. Mahmoudi M.J., Hedayat M., Taghvaei M. et al. Interleukin-10 and Transforming growth factor beta-1 gene polymorphisms in chronic heart failure. Acta Biomed. ‒ 2019. 23; 90(2). 221-227. DOI: 10.23750/abm.v90i2.6681.
Review
For citations:
Ankudinov A.S., Kalyagin A.N., Vikhareva E.E. ASSOCIATIONS OF INTERLEUKIN-6 AND INTERLEUKIN-10 WITH SOME INDICATORS OF THE SEVERITY OF CHRONIC HEART FAILURE AGAINST THE BACKGROUND OF RHEUMATOID ARTHRITIS. Transbaikalian Medical Bulletin. 2021;(2):10-17. (In Russ.) https://doi.org/10.52485/19986173_2021_2_10
Views:
89
Email this article 